IDIBAPS is among the candidates selected for the Carlos III Health Institute’s Fortalece-Salud programme. The successful proposal revolves around six research groups, three focusing on translational research and three on clinical research. Over four years, a total of 2.5 million euros will be devoted to promoting this institutional programme, which is part of the IDIBAPS strategic plan.
The objective of the project, known as KAIROS (Key Advances for Impact Research in Biomedicine at FRCB-IDIBAPS), is to deepen molecular and genetic understanding of various diseases, and to develop and improve diagnostics and personalised treatments. Examples include solid tumours, haematological malignancies and neuropsychiatric and chronic diseases. The six groups will use and continue to develop cutting-edge technologies including single-cell analysis, 3D models, organoids and advanced therapies, as well as computational and artificial intelligence approaches. All this will have a catalytic effect on other IDIBAPS groups and the institution's scientific and technical platforms, and will generate new interdisciplinary projects within IDIBAPS itself, at both national and international level. Moreover, to ensure that the work is aligned with patients’ needs, the programme will also include input from representatives from patient associations as members of the Advisory Group.
The leaders of the groups taking part in the programme are: Sònia Guedan (Cellular immunities for cancer); Itziar Salaverria (Molecular genetics of paediatric lymphomas); Armando López-Guillermo (Lymphoid neoplasms); Susana Puig (Melanoma: imaging, genetics and immunology); Pau Sancho-Bru (Liver cell plasticity and tissue repair); and Gisela Sugranyes (Multimodal neuroimaging in high risk and early psychosis).
